The rating was revealed to investors in a research note on Thursday morning. The 52-week high of Regeneron Pharmaceuticals, Inc. Nine analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. This means 45% are positive. The company has a 52-week high of $605.9299. The stock has a 50 day moving average of $519.03 and a 200-day moving average of $519.95.
Advertisement
REGN continues to expect “initial gradual uptake” at launch and that it will take several months for commercial and gov’t payers to conduct formulary decisions and take claims. (NASDAQ:REGN) ended Tuesday session in red amid volatile trading. Morgan Stanley upped their target price on shares of Regeneron Pharmaceuticals from $489.00 to $499.00 and gave the stock an “outperform” rating in a research note on Monday.
Many analysts have commented on the company rating. The rating by the firm was issued on October 2, 2015. Roth Capital reiterated a “hold” rating and set a $527.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 28th.
The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments – commencing one year after the date of grant.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 2.42% on Wednesday, reaching $564.00. It has outperformed by 26.98% the S&P500. 75 funds bought stakes while 168 increased positions. 911,967 shares of the company were exchanged. A few of them are: Lagoda Investment Management L.P., Pinnacle Associates Ltd, Ray Gerald L & Associates Ltd, Sands Capital Management Llc, Jw Asset Management Llc, Artisan Partners Limited Partnership, Ithaka Group Llc, March Altus Capital Management Lp, Polen Capital Management Llc, Truenorth Inc. Jw Asset Management Llc owns 48,619 shares or 7.54% of their USA portfolio.
Since February 25, 2015, the stock had 3 insider purchases, and 17 insider sales for $60.77 million net activity. 2 analysts have suggested buy for the shares. In addition Cg Asset Management Llc have 2.23% of their stock portfolio invested in the company’s market cap for 11,455 shares. The insider Poon Christine A sold 112 shares worth $63,186.
Advertisement
Regeneron Pharmaceuticals, Inc.is an integrated biopharmaceutical company that discovers, invents, develops, produces and commercializes medicines for the treatment of serious medical conditions. The company has a market cap of $59,932 million and the number of outstanding shares have been calculated to be 103,688,402 shares. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. Regenerons discovery platforms are created to identify specific proteins of therapeutic interest for a particular disease or cell type and validate these targets through high-throughput production of genetically modified mice using the Companys VelociGene technology to understand the role of these proteins in normal physiology, as well as in models of disease. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. The Company has 17 product candidates in clinical development.
